The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min)....

Full description

Saved in:
Bibliographic Details
Published in:Calcified tissue international 1991-12, Vol.49 (6), p.433-435
Main Authors: DALEY-YATES, P. T, DODWELL, D. J, PONGCHAIDECHA, M, COLEMAN, R. E, HOWELL, A
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Biological and medical sciences
Biological Availability
Bone Neoplasms - drug therapy
Bone Neoplasms - metabolism
Bone Neoplasms - secondary
Breast Neoplasms - metabolism
Diphosphonates - pharmacokinetics
Diphosphonates - therapeutic use
Diphosphonates - urine
Diseases of the osteoarticular system
Female
Humans
Injections, Intravenous
Medical sciences
Middle Aged
Miscellaneous. Osteoarticular involvement in other diseases
Pamidronate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min). The renal clearance (74 +/- 34 ml/min) was similar to the creatinine clearance (66 +/- 19 ml/min). Most of the renal elimination occurred during and immediately post a 4 h infusion of the drug (23.2 +/- 7.9% in 24 h). The non-renal clearance was ascribed to uptake by bone and deep tissue compartments. Little additional drug appeared in the urine after 24 h. The mean bioavailability was estimated using a parallel study design to be 0.3% for a 300 mg oral dose.
ISSN:0171-967X
1432-0827
DOI:10.1007/BF02555856